Clinical trials: Multiple sclerosis

Useful therapies are available for virtually every patient with multiple sclerosis. FDA-approved medications currently in use have had major beneficial impact on disease activity in many patients, but we must do better. We must develop therapies with even more potency in disease control, less potential of toxicity, and improved ease of administration and patient comfort.

Questions? Please call:
Providence Multiple Sclerosis Center
Phone: 503-216-1150 Fax: 503-216-1066

Current clinical trials under way at Providence Multiple Sclerosis Center

Pacific Northwest Multiple Sclerosis Registry

The Registry is an ongoing research project enrolling participants who are 18 years of age or older and have a diagnosis of MS. The goal of this registry is to estimate the number of people living with MS in the Northwest and to develop a database for MS research. Participation in the registry is voluntary. If you participate, you will be asked to answer survey questions about yourself and your diagnosis when you sign up and one to two surveys per year about your MS, the MS treatment you receive, and the impact of MS you experience. To learn more about the registry, please visit the Pacific Northwest MS Registry or call 503-216-1022.

Principal investigator: Stanley Cohan, M.D., Ph.D. 

STRIVE:  A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

  • The purpose of the study is to find out if there are any assessments that predict whether or not patients receiving Tysabri will remain free of disease (that is, without relapses, worsened disability, and/or lesions on brain magnetic imaging [MRI] scans).

Principal investigator: Stanley Cohan, M.D., Ph.D.
Sponsor: Biogen Idec
For more information please call Lynette Rogers, CCRP at 503 216-1034.

ASCEND: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects with Secondary Progressive Multiple Sclerosis

  • The purpose of this study is to look at whether the drug natalizumab is effective in slowing the ongoing disability that occurs in secondary progressive multiple sclerosis, whether or not there is a relapse

Principal investigator: Stanley Cohan, M.D., Ph.D.
Sponsor: Biogen Idec
For more information please call Chad Parks, CCRP at 503 216-2736.

OPEXA: A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects with Secondary Progressive Multiple Sclerosis

  • The purpose of this study is to evaluate the safety and effectiveness of Tcelna, when compared to placebo, in reducing the signs of secondary progressive multiple sclerosis.

Principal investigator: Stanley Cohan, M.D., Ph.D.
Sponsor: Opexa Therapeutics, Inc.
For more information please call Crystal Turner, CCRP at 503 216-1017.

OPERA: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients with Relapsing Multiple Sclerosis

  • The purpose of this study is to evaluate the safety and effectiveness of the investigational drug ocrelizumab (IV infusion) to see if it improves the signs and symptoms of multiple sclerosis

Principal investigator: Stanley Cohan, M.D., Ph.D.
Sponsor: Hoffman-LaRoche
For more information please call Chad Parks, CCRP, at 503 216-2736.

ABATACEPT:  A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults with Relapsing-remitting Multiple Sclerosis

  • The purpose of this study is to find out if the experimental drug, Abatacept, is safe and effective in the treatment of patients with relapsing/remitting multiple sclerosis.  Abatacept (IV infusion) is approved by the FDA to treat rheumatoid arhtritis in adults and juvenile inflammatory arthritis in children.

Principal investigator: Stanley Cohan, M.D., Ph.D.
Sponsor: NIAID
For more information please call Chad Parks, CCRP, at 503 216-2736.

FINGOLIMOD OBSERVATIONAL: Long term, prospective, observational, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapy

Principal investigator: Stanley Cohan, M.D., Ph.D.
Sponsor: Novartis
For more information please call Lynette Rogers, CCRP at 503 216-1034.

RELAXIN:  Measurement of Relaxin in the Serum and Cerebrospinal Fluid of Subjects With and Without the Relapsing Form of Multiple Sclerosis.

  • Indication:  This study involves three groups of patients undergoing a lumbar puncture.
    • Group 1:  Patients suspected of having multiple sclerosis
    • Group 2:  Patients with clinically stable multiple sclerosis
    • Group 3:  Patients who do not have multiple sclerosis, but are having a lumbar puncture for some other purpose
  • The purpose of this study is to obtain samples of spinal fluid and blood to be able to compare the levels of Relaxin among three groups of patients

Principal Investigator:  Stanley Cohan, M.D., PhD.
Sponsor:  Providence 
For more information, please contact Crystal Turner, CCRP at 503 216-1017